
Shares of therapy developer Immuneering Corp.IMRX.O rise 7% to $7.08
Company posts Q3 net loss of 38 cents per share compared to analysts' estimated loss of 39 cents per share
Cash, and cash equivalents as of September 30 were $227.6 million, compared with $36.1 million as of December 31, 2024
Including session's moves, stock has more than tripled YTD